Therapeutic correction of endothelial dysfunction: data of the translational medicine

Molecular mechanisms for the mend of functional condition of epithelial cells have been studied by the example of trimetazidine treatment of the patients with arterial hypertension and have been confirmed by in vitro simulation of endothelial dysfunction in cell culture HUVEC. It has been revealed that trimetazidine treatment increases VEGF production and synthesis of ERK, normalization of intracellular calcium concentration and free radicals level in endothelial cells. These molecular changes result in reduced apoptosis of endothelial cells, enhancing their functional activity and cell growth, accompanied by the decrease in the formation of cell membrane microparticles. Membrane microparticles play a key role not only in the development of endothelial dysfunction, but also they are as paracrine regulators of cell survival due to «dumping» excess of signaling proteins by endothelial-derived microparticles.

1. Contreras F., Rivera M., Vásquez J. et al. Endothelial dysfunction in arterial hypertension // J. Hum. Hypertens. 2000. 14. (Suppl. 1). 20–25.

2. Ferroni P., Basili S., Paoletti V. et al. Endothelial dysfunction and oxidative stress in arterial hypertension // Nutr. Metab. Cardiovasc. Dis. 2006. 16. 222–233.

3. Thuillez C., Richard V. Targeting endothelial dysfunction in hypertensive subjects // J. Hum. Hypertens. 2005. 19. 21–25.

4. Tousoulis D., Papageorgiou N., Androulakis E. et al. Novel therapeutic strategies targeting vascular endothelium in essential hypertension // Expert Opin. Investig. Drugs. 2010. 19. (11). 1395–1412.

5. Wilasrusmee C., Da Silva M., Singh B. et al. A new in vitro model to study endothelial injury // J. Surg. Res. 2002. 104. (2). 131–136.

6. Chong A.-Y., Blann A.D., Lip G.Y.H. Assessment of endothelial damage and dysfunction: observations in relation to heart failure // Q. J. Med. 2003. (96). 253–267.

7. Inzhutova A.I., Salmina A.B., Petrova M.M. et al. Detection of plasma membrane blebbing of peripheral blood lymphocytes as a express method of risk stratification in patients with complicated forms of arterial hypertension // Bulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2007. 123. (1). 6-10. (in Russian)

8. Dignat-George F., Boulanger C.M. The many faces of endothelial microparticles // Arterioscler. Thromb. Vasc. Biol. 2011. (31). 27–33.

9. Yuana Y., Bertina R.M., Osanto S. Pre-ana­ly­tical and analytical issues in the analysis of blood microparticles // Thromb. Haemost. 2011. (105). 396–408.

10. Tushuizen M.E., Diamant M., Sturk A. et al. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe? // Arterioscler. Thromb. Vasc. Biol. 2011. 31. (1). 4–9.

11. Corretti M.C., Anderson T.J., Benjamin E.J. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force // JACC. 2002. 39. (2). 257–265.

12. Fish J.E., Matouk C.C., Yeboah E. et al. Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase // J. Biol. Chem. 2007. 282. (21). 15652–15666.

13. Stempien-Otero A., Karsan A., Cornejoi C.J. et al. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis // J. Biol. Chem. 1999. 274. (12). 8039–8045.

14. Yamagishi S., Inagaki Y., Nakamura K. et al. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties // J. Cardiovasc. Pharmacol. 2004. (43). 724–730.

15. Demaison L., Fantini E., Sentex E. et al. Tri­me­tazidine: in vitro influence on heart mitochondrial function // Am. J. Cardiol. 1995. 76. (6). 31–37.

16. He S., Yan F., Zhan J. et al. Protective effects of trimetazidine against vascular endothelial cell injury induced by oxidation // J. Geriatr. Cardiol. 2008. (5). 248–251.

17. Suzuki H., Seto K., Shinoda Y. et al. Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed Hep G2 cells // Am. J. Physiol. Gastrointest. Liver. Physiol. 1999. 276. G92–G97.

18. Izuta H., Chikaraishi Y., Adachi T. et al. Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients // Molecular Vision. 2009. 15. 2663–2672.

19. Iwata Y., Kuzuya F., Hayakawa M. et al. Circulating endothelial cells fail to induce cerebral infarction in rabbits // Stroke. 1986. 17. (3). 506–509.

20. Pirro M., Schillaci G., Paltriccia R. et al. Increased ratio of CD31⁺/CD42^- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia // Arterioscler. Thromb. Vasc. Biol. 2006. 26. 2530–2535.

21. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors // FASEB J. 1999. 13. 9–22.

22. Kantor P.F., Lucien A., Kozak R., Lopas­chuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase // Circ. Res. 2000. 86. 580–588.

23. Lopaschuk G., Stanley W. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potentials for pharmacological intervention // Cardiovasc. Res. 1997. 33. 243–257.

24. Cromer W., Jennings M.H., Odaka Y. et al. Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction // Microcirculation. 2010. 17. (7). 536–547.

25. Argaud L., Gomez L., Gateau-Roesch O. et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury // J. Mol. Cell. Cardiol. 2005. 39. (6). 893–899.

26. Morin D., Sapena R., Elimadi A., Testa B. et al. [³H]-Trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance // Br. J. Pharmacol. 2000. 130. (3). 655–663.

27. Devynck M.A., Le Quan Sang K.H., Joulin Y., Mazeaud M. Acute membrane effects of trimetazidine in human platelets // Eur. J. Pharmacol. 1993. 245. (2). 105–110.

28. Di Napoli P. Anti-ischemic cardioprotection with trimetazidine. Focus on vastarel MR // Heart Metab. 2008. 41. 25–29.

29. Inzhutova A.I., Larionov A.A., Petrova M.M., Salmina A.B. Stabilization of cellular membranes as a target of vascular therapy // Kardiologiya. 2011. (4). 52–55. (in Russian)

30. Goon P.K.Y., Lip G.Y.H., Boos C.J. et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer // Neoplasia. 2006. 8. (2). 79–88.

31. Boos C.J., Lip G.Y.H., Blann A.D. Circulating endothelial cells in cardiovascular disease. // J. Am. Coll. Cardiol. 2006. 48. 1538–1547.

32. Reneman R.S., Arts T., Hoeks A.P.G. Wall shear stress – an important determinant of endothelial cell function and structure – in the arterial system in vivo // J. Vasc. Res. 2006. 43. 251–269.

33. Woywodt A., Bahlmann F.H., de Groot K. et al. Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer // Nephrol. Dial. Transplant. 2002. 17. (10). 1728–1730.

34. Mack M., Kleinschmidt A., Brühl H. et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection // Nat. Med. 2000. (6:7). 769–775.

35. Bebawy M., Combes V., Lee E. et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells // Leukemia. 2009. 23. 1643–1649.